BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 1558402)

  • 41. CA72-4: a new tumour marker for gastric cancer.
    Byrne DJ; Browning MC; Cuschieri A
    Br J Surg; 1990 Sep; 77(9):1010-3. PubMed ID: 2207563
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Multi-antibody combined determination of lymph node micrometastasis in patients with gastric cancer].
    Wang GY; Wang SJ; Li Y; Wang LL; Wang XL; Song ZC; Fan LQ
    Ai Zheng; 2004 May; 23(5):559-63. PubMed ID: 15142454
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
    Kaneko Y; Imoto S; Kasakura S
    Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum CA 19-9, SLX, STN and CEA levels of the peripheral and the draining venous blood in gastric cancer.
    Imada T; Rino Y; Takahashi M; Hatori S; Shiozawa M; Amano T; Kondo J
    Hepatogastroenterology; 1999; 46(27):2086-90. PubMed ID: 10430402
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
    al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
    Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [An autopsy case of a gastric cancer associated with elevated AFP, CEA and CA19-9].
    Nakamura Y; Hozumi T; Ohkita M; Masuda S; Maeda M; Okada K; Chinzei T; Yamashiro K; Harui M; Hosokawa I
    Gan No Rinsho; 1988 Feb; 34(2):213-8. PubMed ID: 2450214
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The clinical information value of an immunoenzyme study of the tumor markers CA-19-9, CEA and AFP in cancer of the stomach, pancreas, colon and rectum].
    Ial'chenko NA; Lagutin VD; Lavik NN; Musin II
    Vopr Onkol; 1991; 37(9-10):921-4. PubMed ID: 1726842
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Usefulness of preoperative assay CEA and CA 19-9 in colorectal cancer patients].
    Grotowski M; MaruszyƄski M; Piechota W
    Pol Merkur Lekarski; 2001 Dec; 11(66):476-9. PubMed ID: 11899841
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lymphatic advancement to peritoneal dissemination and liver metastasis in gastric cancer patients.
    Maehara Y; Tomisaki S; Oda S; Sakaguchi Y; Ichiyoshi Y; Sugimachi K
    Anticancer Res; 1994; 14(6B):2755-7. PubMed ID: 7872713
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The significance of pepsinogen with its subgroup and CA72-4 associate detect applied to early diagnostic and prognosis judgment on gastric cancer].
    Lin HZ; Chen L; Li XC; Zhou DF; Cui JY
    Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(24):1505-8. PubMed ID: 15733483
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer.
    Gao Y; Wang J; Zhou Y; Sheng S; Qian SY; Huo X
    Sci Rep; 2018 Feb; 8(1):2732. PubMed ID: 29426902
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
    Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
    Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An Alternative Method for Screening Gastric Cancer Based on Serum Levels of CEA, CA19-9, and CA72-4.
    Yu J; Zheng W
    J Gastrointest Cancer; 2018 Mar; 49(1):57-62. PubMed ID: 28028765
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
    Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Gastrointestinal cancer].
    Takahashi Y
    Gan To Kagaku Ryoho; 2004 Aug; 31(8):1275-9. PubMed ID: 15332558
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer.
    Kim HJ; Lee KW; Kim YJ; Oh DY; Kim JH; Im SA; Lee JS
    Acta Oncol; 2009; 48(3):385-90. PubMed ID: 18855156
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Utility of dopa decarboxylase as a novel marker for the detection of peritoneal micro-metastases of gastric cancer with realtime RT-PCR].
    Sakakura C; Takemura M; Miyagawa K; Fukuda K; Shimomura K; Kin S; Nakase Y; Kuriu Y; Nakashima S; Yoshikawa T; Ueda Y; Fujiyama J; Sonoyama T; Okazaki Y; Hayashizaki Y; Hagiwara A; Yamagishi H
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1906-8. PubMed ID: 15553755
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Standards, options and recommendations for tumor markers in colorectal cancer].
    Eche N; Pichon MF; Quillien V; Gory-Delabaere G; Riedinger JM; Basuyau JP; Daver A; Buecher B; Conroy T; Dieu L; Bidart JM; Deneux L;
    Bull Cancer; 2001 Dec; 88(12):1177-206. PubMed ID: 11792611
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative detection of carcinoembryonic antigen messenger RNA in the peritoneal cavity of gastric cancer patients by real-time quantitative reverse transcription polymerase chain reaction.
    Ueno H; Yoshida K; Hirai T; Kono F; Kambe M; Toge T
    Anticancer Res; 2003; 23(2C):1701-8. PubMed ID: 12820444
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Indicative value of carcinoembryonic antigen (CEA) for liver recurrence following curative resection of stage II and III gastric cancer.
    Ikeda Y; Mori M; Kajiyama K; Kamakura T; Maehara Y; Haraguchi Y; Sugimachi K
    Hepatogastroenterology; 1996; 43(11):1281-7. PubMed ID: 8908563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.